![]() ![]() 3, 4 Furthermore, patients often do not comply with this frequency of drug administration. In an outpatient clinical setting, current preferred therapeutic strategies for ocular burn include instillation of topical ophthalmic solution of corticosteroid and antibiotic drugs at hourly intervals. ![]() Recommended therapeutic regimens for modulation the ocular surface response to trauma requires multiple dosing and this frequent dosing schedule may not be feasible in critically ill patients in intensive care. These physiological mechanisms also limit the efficacy of topically applied ophthalmic solutions. However, achieving therapeutic concentration of drug on the ocular surface remains a challenge due to the continuous basal production of tears, rapid blinking, and tear clearance through the nasolacrimal drainage system. Presently, eye injuries are treated with topical ophthalmic solutions, which need to be instilled several times in a day for maintaining a therapeutic concentration of the drug at the site of injury. A significant lower number of neutrophils was found in both Dex treatment groups and this was accompanied by decreased MPO activity compared with vehicle controls.ĭex-NW has efficacy equal to Dex drops in preserving corneal clarity and decreasing expression of MMPs and inflammatory cytokines of the corneas of mice subjected to an OB+DS model. Both Dex drops and Dex-NW significantly decreased expression of IL-1β, IL-6, and MMP-9 RNA transcripts compared with vehicle drops or wafers 2 and 5 days after the initial lesion. Myeloperoxidase activity (MPO) was measured using a commercial kit in cornea lysates.īoth Dex drop and Dex-NW groups had significantly lower corneal opacity scores compared with their vehicles. Quantitative PCR evaluated the expression of inflammatory cytokines IL-1β and IL-6 and matrix metalloproteinases (MMP) in whole cornea lysates. Clinical parameters were evaluated daily. C57BL/6 mice were subjected to unilateral alkali ocular burn with concomitant desiccating stress for 2 or 5 days and topically treated either with 2 μL of 0.1% Dex or vehicle four times per day and compared with mice that had MC-NW or Dex-NW placed on their corneas. Nanowafers (NW) loaded with Dexamethasone (Dex, 10 μg) or vehicles (2.5% Methylcellulose MC) were fabricated using hydrogel template strategy. To evaluate the efficacy of a controlled release dexamethasone delivery system for suppressing inflammation in an ocular burn + desiccating stress (OB+DS) model. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |